Advice
following a full submission
indacaterol (Onbrez Breezhaler)is accepted for use within NHS Scotland.
Indication under review: maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).
Indacaterol has been found to be statistically superior to placebo and other long-acting bronchodilators in improving lung function (FEV1) after 12 weeks.
Another long-acting beta2 agonist is available at lower cost.
Download detailed advice94KB (PDF)
Medicine details
- Medicine name:
- indacaterol (Onbrez Breezhaler)
- SMC ID:
- 619/10
- Indication:
- Maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD)
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 August 2010